<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2211200279
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEURITAM
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        50.499
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAUDI PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAUDI PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1023]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAUDI PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).</p><p>Neuritam is used:</p><ul><li>On its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.</li><li>As an add-on to other antiepileptic medicines to treat:<ul><li>Partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age.</li><li>Myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.</li><li>Primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).</li></ul></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Neuritam</strong><br />If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in Section 6).</p><p><strong>Warnings and Precautions</strong><br />Talk to your doctor before taking Neuritam</p><ul><li>If you suffer from kidney problems, follow your doctor&rsquo;s instructions. He/she may decide if your dose should be adjusted.</li><li>If you notice any slowdown in the growth or unexpected puberty development of your child, please contact your doctor.</li><li>A small number of people being treated with anti-epileptics such as Neuritam have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.</li></ul><p>Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:</p><ul><li>Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour.</li></ul><p><strong>Children and adolescents</strong><br />Neuritam is not indicated in children and adolescents below 16 years on its own (monotherapy).</p><p><strong>Other medicines and Neuritam</strong><br />Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.</p><p>Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a reduction of its effect.</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor.<br />You should not stop your treatment without discussing this with your doctor.<br />A risk of birth defects for your unborn child cannot be completely excluded.<br />Breast-feeding is not recommended during treatment.<strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong><br />Neuritam may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.</p><p><strong>Neuritam 500 mg Film-coated Tablets contain lake sunset yellow</strong><br />Lake sunset yellow colouring agent may cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />Take the number of tablets following your doctor&rsquo;s instructions.<br />Neuritam must be taken twice a day, once in the morning and once in the evening, at about the same time each day.</p><p><strong><em>Monotherapy</em><br />Dose in adults and adolescents (from 16 years of age):</strong><br /><u>General dose:</u> Between 1000 mg and 3,000 mg each day.<br />When you will first start taking Neuritam, your doctor will prescribe you a <strong>lower dose </strong>during 2 weeks before giving you the lowest general dose.<br /><em>Example: if your daily dose is 1000 mg, your reduced starting dose is 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening.</em></p><p><strong><em>Add-on therapy</em></strong><br /><strong>Dose in adults and adolescents (12 to 17 years)<strong> </strong>weighing 50 kg or more:</strong><br /><u>General dose:</u> Between 1,000 mg and 3,000 mg each day.<br /><em>Example: if your daily dose is 1,000 mg, you might take 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening.</em><strong>&nbsp;</strong></p><p><strong>Dose in infants (1 month to 23 months), children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:</strong><br />Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to the age, weight and dose.<br />Neuritam 100 mg/ml Oral Solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescent (from 6 to 17 years) weighing less than 50 kg and when tablets don&rsquo;t allow accurate dosage.</p><p><u>Method of administration</u><br />Swallow Neuritam tablets with a sufficient quantity of liquid (<em>e.g</em>. a glass of water). You may take Neuritam with or without food. After oral administration the bitter taste of levetiracetam may be experienced.</p><p><u>Duration of treatment</u></p><ul><li>Neuritam is used as a chronic treatment. You should continue Neuritam treatment for as long as your doctor has told you.</li><li>Do not stop your treatment without your doctor&rsquo;s advice as this could increase your seizures.</li></ul><p><strong>If you take more Neuritam than you should</strong><br />The possible side effects of an overdose of Neuritam are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.<br />Contact your doctor if you took more tablets than you should. Your doctor will establish the best possible treatment of overdose.</p><p><strong>If you forget to take Neuritam</strong><br />Contact your doctor if you have missed one or more doses.<br />Do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you stop taking Neuritam</strong><br />If stopping treatment, Neuritam should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your Neuritam treatment, he/she will instruct you about the gradual withdrawal of Neuritam.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<strong>&nbsp;</strong></p><p><strong>Tell your doctor immediately, or go to your nearest emergency department, if you experience:</strong></p><ul><li>Weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction.</li><li>Swelling of the face, lips, tongue and throat (Quincke&rsquo;s oedema).</li><li>Flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]).</li><li>Symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function.</li><li>A skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (<em>erythema multiforme</em>).</li><li>A widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (<em>Stevens-Johnson syndrome</em>).</li><li>A more severe form of rash causing skin peeling in more than 30% of the body surface (<em>toxic epidermal necrolysis</em>).</li><li>Signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.</li></ul><p>The most frequently reported side effects are nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.</p><p><strong>Very common</strong>: may affect more than 1 in 10 people</p><ul><li>Nasopharyngitis;</li><li>Somnolence (sleepiness), headache.</li></ul><p><strong>Common</strong>: may affect up to 1 in 10 people</p><ul><li>Anorexia (loss of appetite);</li><li>Depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;</li><li>Convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);</li><li>Vertigo (sensation of rotation);</li><li>Cough;</li><li>Abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;</li><li>&nbsp;Rash;</li><li>Asthenia/fatigue (tiredness).</li></ul><p><strong>Uncommon</strong>: may affect up to 1 in 100 people</p><ul><li>Decreased number of blood platelets, decreased number of white blood cells;</li><li>Weight decrease, weight increase;</li><li>Suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;</li><li>Amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);</li><li>Diplopia (double vision), vision blurred;</li><li>Elevated/abnormal values in a liver function test;</li><li>Hair loss, eczema, pruritus;</li><li>Muscle weakness, myalgia (muscle pain);</li><li>Injury.</li></ul><p><strong>Rare</strong>: may affect up to 1 to in 1000 people</p><ul><li>Infection;</li><li>Decreased number of all blood cell types;</li><li>Severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke&rsquo;s oedema [swelling of the face, lips, tongue and throat]);</li><li>Decreased blood sodium concentration;</li><li>Suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);</li><li>Delirium;</li><li>Encephalopathy (see sub-section &ldquo;Tell your doctor immediately&rdquo; for a detailed description of symptoms);</li><li>Uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);</li><li>Pancreatitis;</li><li>Liver failure, hepatitis;</li><li>Sudden decrease in kidney function;</li><li>Skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (<em>erythema multiforme</em>), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (<em>Stevens-Johnson syndrome</em>), and a more severe form causing skin peeling in more than 30% of the body surface (<em>toxic epidermal necrolysis</em>);</li><li>Rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.</li><li>Limp or difficulty walking.</li></ul><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store below 30&deg;C.<br />Do not use this medicine after the expiry date which is stated on the strip and carton. The expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask the pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is called levetiracetam.<br />One tablet of Neuritam 250 mg film-coated tablet contains 250 mg of levetiracetam.<br />One tablet of Neuritam 500 mg film-coated tablet contains 500 mg of levetiracetam.</p><p>The other ingredients are:<br /><u>Tablet core:</u> Croscarmellose sodium, polyethylene glycol, colloidal anhydrous silica and magnesium stearate.<br /><u>Film-coating:</u><br />250 mg tablets: Polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.<br />500 mg tablets: Ferric oxide (red), ferric oxide (yellow), lake sunset yellow, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Neuritam 250 mg Film-coated Tablets are white colored, elliptical, biconvex, film coated tablets with "S129" engraving on one side.
Neuritam 500 mg Film-coated Tablets are yellow colored, elliptical, biconvex, film coated tablets with "S128" engraving and break line on one side. The break line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Neuritam tablets are packaged in cardboard boxes containing 30 tablets (10 tablets x 3 strips).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Pharmaceutical Industries<br />P.O. Box No.: 355127, Riyadh 11383<br />Kingdom of Saudi Arabia.<br />Tel: (+96611) 2650450, 2650354<br />Fax: (+96611) 2650383<br />Email: info@saudi-pharma.net</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ليفيتيراسيتام دواء مضاد للصرع (دواء يستخدم لعلاج نوبات الصرع).</p><p dir="RTL">يستخدم نيوريتام:</p><ul dir="rtl"><li>بمفرده لدى البالغين والمراهقين من عمر 16 سنة الذين تم تشخيصهم بالصرع حديثاً، لمعالجة نوع محدد من الصرع. الصرع هو حالة يعاني المريض فيها من نوبات متكررة. يستخدم ليفيتيراسيتام لعلاج نوع من الصرع تؤثر فيه النوبات في البداية على جانب واحد من الدماغ (نوبات جزئية البدء مع أو دون تعمم ثانوي). تم إعطاؤك ليفيتيراسيتام من قبل طبيبك لتقليل عدد النوبات.</li><li>كعلاج مساعد مع أدوية أخرى مضادة للصرع في:<ul><li>النوبات جزئية البدء مع أو دون تعمم ثانوي لدى البالغين والمراهقين والأطفال والرضع من عمر شهر واحد.</li><li>النوبات الرمعية العضلية (نفضات قصيرة شبيهة بالارتجاج لعضلة أو مجموعة من العضلات) لدى البالغين والمراهقين من عمر 12 سنة المصابين بالصرع الرمعي العضلي اليفعي (الصبياني).</li><li>النوبات التوترية &ndash; الرمعية الأولية (نوبات كبيرة تتضمن فقد الوعي) لدى البالغين والمراهقين من عمر 12 سنة المصابين بصرع معمم مجهول السبب (نوع من الصرع يعتقد بأن له سبباً وراثياً).</li></ul></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول نيوريتام</strong><br />إذا كنت حساساً لليفيتيراسيتام أو مشتقات البيروليدون أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><br />تكلم مع طبيبك أو الصيدلي قبل تناول نيوريتام</p><ul dir="rtl"><li>إذا كنت تعاني من مشاكل في الكلى، اتبع تعليمات طبيبك. فهو من سيقرر فيما إذا كان ينبغي تعديل جرعتك.</li><li>إذا لاحظت أي بطء في النمو أو تطور غير متوقع في بلوغ طفلك فيرجى الاتصال بطبيبك.</li><li>هناك عدد قليل من الأشخاص الذين تمت معالجتهم بأدوية مضادة للصرع مثل نيوريتام كانت لديهم أفكار لإيذاء أوقتل أنفسهم. إذا عانيت من أية أعراض للاكتئاب و/أو التفكير في الانتحار فيرجى الاتصال بطبيبك.</li></ul><p dir="RTL">أخبر طبيبك أو الصيدلي إذا أصبحت أي من الأعراض الجانبية التالية خطيرة أو استمرت أكثر من عدة أيام:</p><ul dir="rtl"><li>أفكار غير طبيعية أو الشعور بسرعة التهيج أو القيام برد فعل أكثر عدوانية من المعتاد، أو إذا لاحظت أنت أو عائلتك أو أصدقاؤك تغيرات مهمة في المزاج أو السلوك.</li></ul><p dir="RTL"><strong>الأطفال والمراهقون</strong><br />لا يوصف نيوريتام بمفرده للأطفال والمراهقين بعمر أقل من 16 سنة (معالجة أحادية الدواء).</p><p dir="RTL"><strong>الأدوية الأخرى ونيوريتام</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخراً أو ربما تتناول أدوية أخرى.</p><p dir="RTL">لا تتناول ماكروغول (دواء يستخدم كملين) قبل ساعة واحدة وبعد ساعة واحدة من تناول ليفيتيراسيتام حيث أن هذا قد يؤدي إلى إنقاص تأثيره.</p><p dir="RTL"><strong>الحمل والإرضاع</strong><br />إذا كنت حاملاً أو مرضعة أو تعتقدين بأنك حامل أو تخططين للحمل فاستشيري طبيبك قبل تناول هذا الدواء. يمكن استخدام ليفيتيراسيتام أثناء الحمل فقط بعد التقييم الدقيق إذا اعتبره طبيبك ضرورياً.<br />يجب ألا توقفي المعالجة دون مشاورة طبيبة.<br />لا يمكن بشكل كامل استبعاد خطر حدوث عيوب خلقية لطفلك (الذي لم يولد بعد).<br />لا يوصى بالإرضاع الطبيعي أثناء المعالجة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />قد يؤدي نيوريتام إلى خلل في قدرتك على القيادة أو تشغيل أية أدوات أو آلات حيث أنه قد يجعلك تشعر بالنعاس. يزداد هذا الاحتمال في بداية المعالجة أو بعد زيادة الجرعة. ينبغي عليك ألا تقوم بالقيادة أو استخدام الآلات حتى تتأكد من أن قدرتك على أداء مثل هذه النشاطات لا تتأثر بالدواء.</p><p dir="RTL"><strong>نيوريتام 500 ملغ أقراص مغلفة تحتوي على صباغ أصفر الغروب</strong><br />صباغ أصفر الغروب مادة ملونة قد تسبب تفاعلات تحسسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً كما أخبرك طبيبك أو الصيدلي. يجب أن تراجع طبيبك أو الصيدلي إذا لم تكن متأكداً.<br />تناول عدد الأقراص حسب تعليمات طبيبك.<br />يجب أن يتم تناول نيوريتام مرتين يومياً، مرة في الصباح وأخرى في المساء، في الوقت نفسه تقريباً من كل يوم.</p><p dir="RTL"><strong>المعالجة أحادية الدواء<br />الجرعة للبالغين والمراهقين (من عمر 16 سنة):</strong><br /><u>الجرعة العامة:</u> بين 1000 ملغ و3000 ملغ كل يوم.<br />عندما تبدأ بتناول نيوريتام للمرة الأولى فإن طبيبك سيصف لك <strong>جرعة أقل </strong>خلال أسبوعين قبل إعطائك أقل جرعة عامة.<br />مثال: إذا كانت جرعتك اليومية 100 ملغ، فإن جرعة البداية المخفضة هي قرصان من تركيز 250 ملغ في الصباح وقرصان من تركيز 250 ملغ في المساء.</p><p dir="RTL"><strong>المعالجة المساعدة<br />الجرعة للبالغين والمراهقين (12 إلى 17 سنة) بوزن 50 كغ أو أكثر:</strong><br /><u>الجرعة العامة:</u> بين 1000 ملغ و3000 ملغ كل يوم.<br />مثال: إذا كانت جرعتك اليومية 1000 ملغ، يمكن أن تتناول قرصين من تركيز 250 ملغ في الصباح وقرصين من تركيز 250 ملغ في المساء.</p><p dir="RTL"><strong>الجرعة للرضع (شهر إلى 23 شهراً) والأطفال (سنتان إلى 11 سنة) والمراهقين (12 إلى 17 سنة) بوزن أقل من 50 كغ:</strong><br />سيقوم طبيبك بوصف الشكل الصيدلاني الأكثر ملائمة من ليفيتيراسيتام حسب العمر والوزن والجرعة.<br />نيوريتام 100 ملغ/مل محلول فموي هو الشكل الصيدلاني الأكثر ملائمة للرضع والأطفال بعمر أقل من 6 سنوات والأطفال والمراهقين (من 6 إلى 17 سنة) بوزن أقل من 50 كغ وعندما لا تسمح الأقراص بالحصول على جرعة دقيقة.</p><p dir="RTL"><u>طريقة الإعطاء</u><br />قم بابتلاع أقراص نيوريتام مع كمية كافية من السوائل (مثلاً، كأس من الماء). يمكنك تناول نيوريتام مع الطعام أو دونه. بعد الإعطاء عن طريق الفم، قد يحدث إحساس بالطعم المر لليفيتيراسيتام.</p><p dir="RTL"><u>مدة المعالجة</u></p><ul dir="rtl"><li>يستخدم نيوريتام كمعالجة مزمنة. يجب أن تستمر بالمعالجة بنيوريتام طوال المدة التي أخبرك طبيبك بها.</li><li>لا تتوقف عن تناول علاجك دون نصيحة الطبيب فقد يزيد ذلك من حدوث النوبات لديك.</li></ul><p dir="RTL"><strong>إذا تناولت نيوريتام أكثر مما ينبغي</strong><br />الأعراض الجانبية المحتملة لزيادة جرعة نيوريتام هي النعاس والهياج والعدوانية وقلة الانتباه وتثبيط التنفس وسبات.<br />اتصل بطيبيك إذا تناولت أقراصاً أكثر مما ينبغي. سيقرر طبيبك ما هي المعالجة الأنسب للجرعة الزائدة.</p><p dir="RTL"><strong>إذا نسيت أن تتناول نيوريتام</strong><br />اتصل بطبيبك إذا نسيت جرعة واحدة أو أكثر.<br />لا تتناول جرعة مضاعفة لتعويض الأقراص المنسية.<strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن تناول نيوريتام</strong><br />لإيقاف المعالجة، ينبغي أن يوقف نيوريتام تدريجياً لتجنب زيادة النوبات. إذا قرر طبيبك إيقاف معالجتك بنيوريتام فسيرشدك حول كيفية السحب التدريجي لنيوريتام.</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى حول استخدام هذا الدواء فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب أعراضاً جانبية إلا أنها قد لا تحدث لدى كل الأشخاص.</p><p dir="RTL"><strong>أخبر طبيبك على الفور أو اذهب إلى أقرب قسم للطوارئ إذا عانيت من:</strong></p><ul dir="rtl"><li>ضعف أو شعور بدوخة أو صعوبة في التنفس، فقد تكون هذه علامات لرد فعل تحسسي شديد (تأقي).</li><li>تورم في الوجه والشفاه واللسان والحنجرة (وذمة كوينكه).</li><li>أعراض مشابهة للانفلونزا وطفح على الوجه متبوع بطفح ممتد مع حرارة عالية، وزيادة مستويات إنزيمات الكبد المشاهدة في اختبارات الدم وزيادة في كريات الدم البيضاء من نمط (كثرة اليوزينيات) وتضخم العقد اللمفية (تفاعل دوائي مع كثرة اليوزينيات وأعراض جهازية [DRESS]).</li><li>أعراض مثل نقص حجم البول والتعب والغثيان والقيء والتخليط وتورم في الرجلين أوالكاحلين أو القدمين حيث أن هذا قد يكون علامة لانخفاض مفاجئ في وظيفة الكلية.</li><li>طفح جلدي قد يؤدي إلى تشكيل نفاطات تشبه النقاط الصغيرة (بقع مركزية قاتمة محاطة بمنطقة أكثر شحوباً مع حلقة قاتمة حول الحافة) (حمامى عديدة الأشكال).</li><li>طفح واسع الانتشار مع نفاطات وجلد متقشر وبخاصة حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز-جونسون).</li><li>شكل أكثر شدة من أشكال الطفح الذي يؤدي إلى تقشر الجلد في أكثر من حوالي 30% من سطح الجسم (تقشر الأنسجة المتموتة البشروية التسممي).</li><li>علامات لتغيرات نفسية شديدة أو إذا لاحظ أحد ما حولك علامات لتخليط أو نيمومة (نعاس) أو فقد الذاكرة أو خلل في الذاكرة (نسيان) أو سلوك غير طبيعي أو علامات عصبية أخرى تتضمن حركات لا إرادية أو خارجة عن السيطرة. قد تكون هذه أعراضاً لاعتلال دماغي.</li></ul><p dir="RTL">أكثر الأعراض الجانبية تكراراً التي تم الإبلاغ عنها هي التهاب البلعوم الأنفي والنيمومة (النعاس) والصداع والتعب والدوخة. في بداية المعالجة أو عند زيادة الجرعة، قد تكون الأعراض الجانبية مثل النعاس والتعب والدوخة أكثر شيوعاً. ومع ذلك فإن هذه الأعراض ينبغي أن تقل مع مرور الوقت.</p><p dir="RTL"><strong>شائعة جداً: </strong>يمكن أن تؤثر على أكثر من 1 من 10 أشخاص</p><ul dir="rtl"><li>التهاب البلعوم الأنفي؛</li><li>نعاس، صداع.</li></ul><p dir="RTL"><strong>شائعة: </strong>يمكن أن تؤثر على 1 من 10 اشخاص</p><ul dir="rtl"><li>فقد الشهية؛</li><li>اكتئاب، عداء، قلق، أرق، عصبية أو تهيج؛</li><li>اختلاج، اضطراب التوازن، دوخة (إحساس بعد الثبات)، خمول (نقص في الطاقة والحماس)، رعاش (ارتعاش لا إرادي)؛</li><li>دوار؛</li><li>سعال؛</li><li>ألم بطني، إسهال، عسر هضم، قيء، غثيان؛</li><li>طفح؛</li><li>وهن.</li></ul><p dir="RTL"><strong>غير شائعة:</strong> يمكن أن تؤثر على 1 من 100 شخص</p><ul dir="rtl"><li>انخفاض عدد صفيحات الدم، انخفاض عدد كريات الدم البيضاء؛</li><li>نقض الوزن، زيادة الوزن؛</li><li>محاولة الانتحار وأفكار انتحارية، اضطراب نفسي، سلوك غير طبيعي، هلوسة، غضب، تخليط، نوبة هلع، تقلب انفعالي/ تقلب المزاج، هياج؛</li><li>فقد الذاكرة، خلل في الذاكرة (نسيان)، تناسق غير طبيعي/فقد الانتظام (اختلال الحركات المنسقة)، مذل (نخز)، اضطراب في الانتباه (فقد التركيز)؛</li><li>شفع (ازدواج الرؤية)، تغيم الرؤية؛</li><li>قيم مرتفعة/غير طبيعية في اختبار وظيفة الكبد؛</li><li>فقد الشعر، إكزيمة، حكة؛</li><li>ضعف عضلي، ألم عضلي؛</li><li>إصابة.</li></ul><p dir="RTL"><strong>نادرة: </strong>يمكن أن تؤثر على 1 من 1000 شخص</p><ul dir="rtl"><li>عدوى؛</li><li>انخفاض في عدد جميع أنواع خلايا الدم؛</li><li>تفاعلات تحسسية شديدة (DRESS تفاعل دوائي مع كثرة اليوزينيات وأعراض جهازية، تفاعل تأقي [تفاعل تحسسي شديد وخطير]، وذمة كوينكه [تورم الوجه والشفاه واللسان والحنجرة])؛</li><li>انخفاض تركيز الصوديوم في الدم؛</li><li>انتحار، اضطراب الشخصية (مشاكل سلوكية)، تفكير غير طبيعي (تفكير بطيء، عدم القدرة على التركيز)؛</li><li>هذيان؛</li><li>اعتلال دماغي (انظر القسم الفرعي &quot;أخبر طبيبك على الفور&quot; لوصف تفصيلي للأعراض)؛</li><li>تشنجات عضلية خارجة عن السيطرة تؤثر على الرأس والجذع والأطراف، صعوبة السيطرة على الحركات، فرط الحراك (فرط النشاط)؛</li><li>التهاب البنكرياس؛</li><li>فشل الكبد، التهاب الكبد؛</li><li>انخفاض مفاجئ في وظيفة الكلية؛</li><li>طفح جلدي قد يؤدي إلى تشكيل نفاطات تشبه النقاط الصغيرة (بقع مركزية قاتمة محاطة بمنطقة أكثر شحوباً مع حلقة قاتمة حول الحافة) (حمامى عديدة الأشكال)، طفح واسع الانتشار مع نفاطات وجلد متقشر وبخاصة حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز-جونسون) بالإضافة إلى شكل أكثر شدة يؤدي إلى تقشر الجلد في أكثر من حوالي 30% من سطح الجسم (تقشر الأنسجة المتموتة البشروية التسممي)؛</li><li>انحلال الربيدات (تحطم في النسيج العضلي) وارتفاع مصاحب لفسفوكيناز الكرياتين في الدم. يلاحظ انتشار أعلى في المرضى اليابانيين مقارنة بالمرضى غير اليابانيين.</li><li>عرج أو صعوبة في المشي.</li></ul><p dir="RTL">إذا أصبت بأية أعراض جانبية فتحدث إلى طبيبك أو الصيدلي. هذا يشمل أيضاً أية أعراض جانبية محتملة غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول ومرأى الأطفال.<br />يخزن عند حرارة أقل من 30&deg;م.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على الشريط والعبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.<br />لا تقم بالتخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تحتاجها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي ليفيتيراسيتام.<br />يحتوي قرص نيوريتام 250 ملغ أقراص مغلفة على 250 ملغ من ليفيتيراسيتام.<br />يحتوي قرص نيوريتام 500 ملغ أقراص مغلفة على 500 ملغ من ليفيتيراسيتام.</p><p dir="RTL">المكونات الأخرى هي:<br /><u>نواة القرص:</u> صوديوم كروس كارميلوز، غليكول بولي إيثيلين، سيليكا غروانية لا مائية، ستيارات المغنيزيوم.<br />التغليف:<br />أقراص 250 ملغ: غليكول بولي إيثيلين، كحول عديد الفاينيل، تالك (طلق)، ثنائي أكسيد التيتانيوم.<br />أقراص 500 ملغ: أكسيد الحديديك (الأحمر)، أكسيد الحديديك (الأصفر)، صباغ أصفر الغروب، غليكول بولي إيثيلين، كحول عديد الفاينيل، تالك (طلق)، ثنائي أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نيوريتام 250 ملغ أقراص مغلفة عبارة عن أقراص بيضاء اللون بيضوية الشكل محدبة الوجهين مغلفة بطبقة رقيقة منقوش عليها &quot;S129&quot; على جانب واحد.<br />نيوريتام 500 ملغ أقراص مغلفة عبارة عن أقراص صفراء اللون بيضوية الشكل محدبة الوجهين مغلفة بطبقة رقيقة منقوش عليها &quot;S128&quot; على جانب واحد ولها خط كسر على الجانب الآخر. خط الكسر فقط لتسهيل الكسر أو تسهيل البلع وليس للتقسيم إلى جرعات متساوية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة السعودية للصناعات الصيدلانية<br />صندوق بريد رقم: 355127، الرياض 11383<br />المملكة العربية السعودية.<br />هاتف: 2650354، 2650450 (96611+)<br />فاكس: 2650383 (96611+)<br />بريد الكتروني: info@saudi-pharma.net</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Neuritam 250 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 250 mg levetiracetam.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
White colored, elliptical, biconvex, film coated tablets with "S129" engraving on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Neuritam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.<br />Neuritam is indicated as adjunctive therapy</p><ul><li>In the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.</li><li>In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</li><li>In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br /><em>Monotherapy for adults and adolescents from 16 years of age</em><br />The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.</p><p><em>Add-on therapy for adults (&ge;18 years) and adolescents (12 to 17 years) weighing 50 kg or more</em><br />The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment.<br />Depending upon the clinical response and tolerability, the daily dose can be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.</p><p><u>Discontinuation</u><br />If levetiracetam has to be discontinued it is recommended to withdraw it gradually (<em>e.g</em>. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighing less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/kg twice daily every two weeks).</p><p><u>Special populations</u><br /><em>Elderly (65 years and older)</em><br />Adjustment of the dose is recommended in elderly patients with compromised renal function (see &ldquo;Renal impairment&rdquo; below).<em>&nbsp;</em></p><p><em>Renal impairment</em><br />The daily dose must be individualised according to renal function.<br />For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:</p><p><img src="data:image/png;base64,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" alt="" width="363" height="36" vspace="0" hspace="0" border="0" style="width:363px;height:36px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><!--[if gte msEquation 12]><m:oMathPara><m:oMathParaPr><m:jc
   m:val="left"/></m:oMathParaPr><m:oMath><span lang=EN-GB style='font-size:
  12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:"Times New Roman";
  mso-bidi-theme-font:major-bidi'><m:r><m:rPr><m:scr m:val="roman"/><m:sty
     m:val="p"/></m:rPr>CLcr (ml/min) = </m:r></span><m:f><m:fPr><span
    style='font-size:12.0pt;mso-ansi-font-size:12.0pt;mso-bidi-font-size:12.0pt;
    font-family:"Cambria Math",serif;mso-ascii-font-family:"Cambria Math";
    mso-hansi-font-family:"Cambria Math";mso-bidi-font-family:"Times New Roman";
    mso-bidi-theme-font:major-bidi;mso-bidi-font-style:italic'><m:ctrlPr></m:ctrlPr></span></m:fPr><m:num><m:d><m:dPr><m:begChr
       m:val="["/><m:endChr m:val="]"/><span style='font-size:12.0pt;
      mso-ansi-font-size:12.0pt;mso-bidi-font-size:12.0pt;font-family:"Cambria Math",serif;
      mso-ascii-font-family:"Cambria Math";mso-hansi-font-family:"Cambria Math";
      mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
      mso-bidi-font-style:italic'><m:ctrlPr></m:ctrlPr></span></m:dPr><m:e><span
      lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
      mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><m:r><m:rPr><m:scr
         m:val="roman"/><m:sty m:val="p"/></m:rPr>140-age </m:r></span><m:d><m:dPr><span
        style='font-size:12.0pt;mso-ansi-font-size:12.0pt;mso-bidi-font-size:
        12.0pt;font-family:"Cambria Math",serif;mso-ascii-font-family:"Cambria Math";
        mso-hansi-font-family:"Cambria Math";mso-bidi-font-family:"Times New Roman";
        mso-bidi-theme-font:major-bidi;mso-bidi-font-style:italic'><m:ctrlPr></m:ctrlPr></span></m:dPr><m:e><span
        lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
        mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><m:r><m:rPr><m:scr
           m:val="roman"/><m:sty m:val="p"/></m:rPr>years</m:r></span></m:e></m:d></m:e></m:d><span
    lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><m:r><m:rPr><m:scr
       m:val="roman"/><m:sty m:val="p"/></m:rPr>×weight (kg)</m:r></span></m:num><m:den><span
    lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><m:r><m:rPr><m:scr
       m:val="roman"/><m:sty m:val="p"/></m:rPr>72×serum creatinine (mg/dl)</m:r></span></m:den></m:f><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
  mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><m:r><m:rPr><m:scr
     m:val="roman"/><m:sty m:val="p"/></m:rPr> (× 0.85 for women)</m:r></span></m:oMath></m:oMathPara><![endif]--></p><p>Then CLcr is adjusted for body surface area (BSA) as follows:</p><p><img src="data:image/png;base64,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" alt="" width="259" height="36" vspace="0" hspace="0" border="0" style="width:259px;height:36px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><!--[if gte msEquation 12]><m:oMathPara><m:oMathParaPr><m:jc
   m:val="left"/></m:oMathParaPr><m:oMath><span lang=EN-GB style='font-size:
  12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr
     m:val="roman"/><m:sty m:val="p"/></m:rPr>CLcr (ml/min/1.73 </m:r></span><m:sSup><m:sSupPr><span
    style='font-size:12.0pt;mso-ansi-font-size:12.0pt;mso-bidi-font-size:12.0pt;
    font-family:"Cambria Math",serif;mso-ascii-font-family:"Cambria Math";
    mso-hansi-font-family:"Cambria Math";mso-bidi-font-family:"Times New Roman";
    mso-bidi-font-style:italic'><m:ctrlPr></m:ctrlPr></span></m:sSupPr><m:e><span
    lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
    mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty
       m:val="p"/></m:rPr>m</m:r></span></m:e><m:sup><span lang=EN-GB
    style='font-size:12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:
    "Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty m:val="p"/></m:rPr>2</m:r></span></m:sup></m:sSup><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
  mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty
     m:val="p"/></m:rPr>) = </m:r></span><m:f><m:fPr><span style='font-size:
    12.0pt;mso-ansi-font-size:12.0pt;mso-bidi-font-size:12.0pt;font-family:
    "Cambria Math",serif;mso-ascii-font-family:"Cambria Math";mso-hansi-font-family:
    "Cambria Math";mso-bidi-font-family:"Times New Roman";mso-bidi-font-style:
    italic'><m:ctrlPr></m:ctrlPr></span></m:fPr><m:num><span lang=EN-GB
    style='font-size:12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:
    "Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty m:val="p"/></m:rPr>CLcr
     (ml/min)</m:r></span></m:num><m:den><span lang=EN-GB style='font-size:
    12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr
       m:val="roman"/><m:sty m:val="p"/></m:rPr>BSA subject </m:r></span><m:sSup><m:sSupPr><span
      style='font-size:12.0pt;mso-ansi-font-size:12.0pt;mso-bidi-font-size:
      12.0pt;font-family:"Cambria Math",serif;mso-ascii-font-family:"Cambria Math";
      mso-hansi-font-family:"Cambria Math";mso-bidi-font-family:"Times New Roman";
      mso-bidi-font-style:italic'><m:ctrlPr></m:ctrlPr></span></m:sSupPr><m:e><span
      lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
      mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty
         m:val="p"/></m:rPr>(m</m:r></span></m:e><m:sup><span lang=EN-GB
      style='font-size:12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:
      "Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty m:val="p"/></m:rPr>2</m:r></span></m:sup></m:sSup><i
    style='mso-bidi-font-style:normal'><span lang=EN-GB style='font-size:12.0pt;
    font-family:"Cambria Math",serif;mso-bidi-font-family:"Times New Roman"'><m:r>)</m:r></span></i></m:den></m:f><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
  mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty
     m:val="p"/></m:rPr> × 1.73</m:r></span></m:oMath></m:oMathPara><![endif]--></p><p>Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="text-align:center; vertical-align:middle"><p><strong>Group</strong></p></td><td style="text-align:center; vertical-align:middle"><p><strong>Creatinine clearance</strong></p><p><strong>(ml/min/1.73 m<sup>2</sup>)</strong></p></td><td style="text-align:center; vertical-align:middle"><p><strong>Dose and frequency</strong></p></td></tr><tr><td><p>Normal</p></td><td><p>&ge; 80</p></td><td><p>500 to 1500 mg twice daily</p></td></tr><tr><td><p>Mild</p></td><td><p>50 &ndash; 79</p></td><td><p>500 to 1000 mg twice daily</p></td></tr><tr><td><p>Moderate</p></td><td><p>30 &ndash; 49</p></td><td><p>250 to 750 mg twice daily</p></td></tr><tr><td><p>Severe</p></td><td><p>&lt; 30</p></td><td><p>250 to 500 mg twice daily</p></td></tr><tr><td><p>End-stage renal disease patients undergoing dialysis <sup>(1)</sup></p></td><td><p>&ndash;</p></td><td><p>500 to 1000 mg once daily <sup>(2)</sup></p></td></tr></tbody></table><p><sup>(1)</sup> A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.<br /><sup>(2)</sup> Following dialysis, a 250 to 500 mg supplemental dose is recommended.</p><p>For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.<br />The CLcr in ml/min/1.73 m<sup>2</sup> may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula):</p><p><!--[if gte msEquation 12]><m:oMathPara><m:oMathParaPr><m:jc
   m:val="left"/></m:oMathParaPr><m:oMath><span lang=EN-GB style='font-size:
  12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr
     m:val="roman"/><m:sty m:val="p"/></m:rPr>CLcr (ml/min/1.73 </m:r></span><m:sSup><m:sSupPr><span
    style='font-size:12.0pt;mso-ansi-font-size:12.0pt;mso-bidi-font-size:12.0pt;
    font-family:"Cambria Math",serif;mso-ascii-font-family:"Cambria Math";
    mso-hansi-font-family:"Cambria Math";mso-bidi-font-family:"Times New Roman";
    mso-bidi-font-style:italic'><m:ctrlPr></m:ctrlPr></span></m:sSupPr><m:e><span
    lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
    mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty
       m:val="p"/></m:rPr>m</m:r></span></m:e><m:sup><span lang=EN-GB
    style='font-size:12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:
    "Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty m:val="p"/></m:rPr>2</m:r></span></m:sup></m:sSup><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
  mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty
     m:val="p"/></m:rPr>) = </m:r></span><m:f><m:fPr><span style='font-size:
    12.0pt;mso-ansi-font-size:12.0pt;mso-bidi-font-size:12.0pt;font-family:
    "Cambria Math",serif;mso-ascii-font-family:"Cambria Math";mso-hansi-font-family:
    "Cambria Math";mso-bidi-font-family:"Times New Roman";mso-bidi-font-style:
    italic'><m:ctrlPr></m:ctrlPr></span></m:fPr><m:num><span lang=EN-GB
    style='font-size:12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:
    "Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty m:val="p"/></m:rPr>Height
     </m:r></span><m:d><m:dPr><span style='font-size:12.0pt;mso-ansi-font-size:
      12.0pt;mso-bidi-font-size:12.0pt;font-family:"Cambria Math",serif;
      mso-ascii-font-family:"Cambria Math";mso-hansi-font-family:"Cambria Math";
      mso-bidi-font-family:"Times New Roman";mso-bidi-font-style:italic'><m:ctrlPr></m:ctrlPr></span></m:dPr><m:e><span
      lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
      mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty
         m:val="p"/></m:rPr>cm</m:r></span></m:e></m:d><span lang=EN-GB
    style='font-size:12.0pt;font-family:"Cambria Math",serif;mso-bidi-font-family:
    "Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty m:val="p"/></m:rPr>×ks</m:r></span></m:num><m:den><span
    lang=EN-GB style='font-size:12.0pt;font-family:"Cambria Math",serif;
    mso-bidi-font-family:"Times New Roman"'><m:r><m:rPr><m:scr m:val="roman"/><m:sty
       m:val="p"/></m:rPr>Serum Creatinine (mg/dl)</m:r></span></m:den></m:f></m:oMath></m:oMathPara><![endif]--></p><p><img src="data:image/png;base64,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" alt="" width="271" height="36" vspace="0" hspace="0" border="0" style="width:271px;height:36px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>ks = 0.45 in term infants to 1 year old; ks = 0.55 in children to less than 13 years and in adolescent female; ks = 0.7 in adolescent male.<br />Dosing adjustment for infants, children and adolescents patients weighing less than 50 kg with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="text-align:center; vertical-align:middle"><p><strong>Group</strong></p></td><td rowspan="2" style="text-align:center; vertical-align:middle"><p><strong>Creatinine clearance</strong></p><p><strong>(ml/min/1.73 m<sup>2</sup>)</strong></p></td><td colspan="2" style="text-align:center; vertical-align:middle"><p><strong>Dose and frequency <sup>(1)</sup></strong></p></td></tr><tr><td style="text-align:center; vertical-align:middle"><p><strong>Infants 1 to less than 6 months</strong></p></td><td style="text-align:center; vertical-align:middle"><p><strong>Infants 6 to 23 months, children and adolescents weighing less than 50 kg</strong></p></td></tr><tr><td><p>Normal</p></td><td><p>&ge; 80</p></td><td><p>7 to 21 mg/kg (0.07 to 0.21 ml/kg) twice daily</p></td><td><p>10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily</p></td></tr><tr><td><p>Mild</p></td><td><p>50 &ndash; 79</p></td><td><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) twice daily</p></td><td><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily</p></td></tr><tr><td><p>Moderate</p></td><td><p>30 &ndash; 49</p></td><td><p>3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily</p></td><td><p>5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily</p></td></tr><tr><td><p>Severe</p></td><td><p>&lt; 30</p></td><td><p>3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily</p></td><td><p>5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily</p></td></tr><tr><td><p>End-stage renal disease patients undergoing dialysis</p></td><td><p>&ndash;</p></td><td><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) once daily <sup>(2) (4)</sup></p></td><td><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily <sup>(3) (5)</sup></p></td></tr></tbody></table><p><sup>(1)</sup> Neuritam Oral Solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.<br /><sup>(2)</sup> A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.<br /><sup>(3)</sup> A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.<br /><sup>(4)</sup> Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.<br /><sup>(5)</sup> Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.</p><p><em>Hepatic impairment</em><br />No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is &lt; 60 ml/min/1.73 m<sup>2</sup>.</p><p><u>Paediatric population</u><br />The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.<br />The tablet formulation is not adapted for use in infants and children under the age of 6 years. Neuritam Oral Solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases Neuritam Oral Solution should be used.</p><p><em>Monotherapy</em><br />The safety and efficacy of Neuritam in children and adolescents below 16 years as monotherapy treatment have not been established.<br />No data are available.<em>&nbsp;</em></p><p><em>Add-on therapy for infants aged 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg</em><br />Neuritam Oral Solution is the preferred formulation for use in infants and children under the age of 6 years.<br />For children 6 years and above, Neuritam Oral Solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.<br />The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dose in children 50 kg or greater is the same as in adults.</p><p><em>Add-on therapy for infants aged from 1 month to less than 6 months</em><br />The oral solution is the formulation to use in infants.</p><p><u>Method of administration</u><br />The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. After oral administration the bitter taste of levetiracetam may be experienced. The daily dose is administered in two equally divided doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Renal impairment</u><br />The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).</p><p><u>Acute Kidney injury</u><br />The use of levetiracetam has been very rarely associated with acute kidney injury, with a time to onset ranging from a few days to several months.</p><p><u>Blood cell counts</u><br />Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders (section 4.8).</p><p><u>Suicide</u><br />Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known.<br />Therefore, patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.</p><p><u>Abnormal and aggressive behaviours</u><br />Levetiracetam may cause psychotic symptoms and behavioural abnormalities including irritability and aggressiveness. Patients treated with levetiracetam should be monitored for developing psychiatric signs suggesting important mood and/or personality changes. If such behaviours are noticed, treatment adaptation or gradual discontinuation should be considered. If discontinuation is considered, please refer to section 4.2.</p><p><u>Paediatric population</u><br />The tablet formulation is not adapted for use in infants and children under the age of 6 years.<br />Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Antiepileptic medicinal products</u><br />Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.<br />As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.<br />A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20% higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.</p><p><u>Probenecid</u><br />Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.</p><p><u>Methotrexate</u><br />Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.</p><p><u>Oral contraceptives and other pharmacokinetics interactions</u><br />Levetiracetam 1000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.</p><p><u>Laxatives</u><br />There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.</p><p><u>Food and alcohol</u><br />The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.<br />No data on the interaction of levetiracetam with alcohol are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of child bearing potential</u><br />Specialist advice should be given to women who are of childbearing potential. Treatment with levetiracetam should be reviewed when a woman is planning to become pregnant. As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicines AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.</p><p><u>Pregnancy</u><br />A large amount of postmarketing data on pregnant women exposed to levetiracetam monotherapy (more than 1800, among which in more than 1500 exposure occurred during the 1<sup>st</sup> trimester) do not suggest an increase in the risk for major congenital malformations. Only limited evidence is available on the neurodevelopment of children exposed to levetiracetam monotherapy in utero. However, current epidemiological studies (on about 100 children) do not suggest an increased risk of neurodevelopmental disorders or delays.<br />Levetiracetam can be used during pregnancy, if after careful assessment it is considered clinically needed. In such case, the lowest effective dose is recommended.<br />Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured.</p><p><u>Breastfeeding</u><br />Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended.<br />However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.</p><p><u>Fertility</u><br />No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam has minor or moderate influence on the ability to drive and use machines. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, <em>e.g</em>. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u><br />The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3416 patients treated with levetiracetam. These data are supplemented with the use of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.</p><p><u>Tabulated list of adverse reactions</u><br />Adverse reactions reported in clinical studies (adults, adolescents, children and infants &gt; 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1000 to &lt; 1/100); rare (&ge; 1/10000 to &lt; 1/1000) and very rare (&lt; 1/10000).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="text-align:center; vertical-align:middle"><p><strong>MedDRA SOC</strong></p></td><td colspan="4" style="text-align:center; vertical-align:middle"><p><strong>Frequency category</strong></p></td></tr><tr><td style="text-align:center; vertical-align:middle"><p><strong>Very common</strong></p></td><td style="text-align:center; vertical-align:middle"><p><strong>Common</strong></p></td><td style="text-align:center; vertical-align:middle"><p><strong>Uncommon</strong></p></td><td style="text-align:center; vertical-align:middle"><p><strong>Rare</strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>Nasopharyngitis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Infection</p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Thrombocytopenia, leukopenia</p></td><td><p>Pancytopenia, neutropenia, agranulocytosis</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Drug reaction with eosinophilia and systemic symptoms (DRESS), Hypersensitivity (including angioedema and anaphylaxis)</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>&nbsp;</p></td><td><p>Anorexia</p></td><td><p>Weight decreased, weight increase</p></td><td><p>Hyponatraemia</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td><p>&nbsp;</p></td><td><p>Depression, hostility/ aggression, anxiety, insomnia, nervousness/ irritability</p></td><td><p>Suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack, affect lability/mood swings, agitation</p></td><td><p>Completed suicide, personality disorder, thinking abnormal, delirium</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Somnolence, headache</p></td><td><p>Convulsion, balance disorder, dizziness, lethargy, tremor</p></td><td><p>Amnesia, memory impairment, coordination abnormal/ataxi, paraesthesia, disturbance in attention</p></td><td><p>Choreoathetosi, dyskinesia, hyperkinesia, gait disturbance, encephalopathy</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Diplopia, vision blurred</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>&nbsp;</p></td><td><p>Vertigo</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>&nbsp;</p></td><td><p>Cough</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>&nbsp;</p></td><td><p>Abdominal pain, diarrhoea, dyspepsia, vomiting, nausea</p></td><td><p>&nbsp;</p></td><td><p>Pancreatitis</p></td></tr><tr><td><p>Hepatobiliary disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Liver function test abnormal</p></td><td><p>Hepatic failure, hepatitis</p></td></tr><tr><td><p>Renal and urinary Disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Acute Kidney injury</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>&nbsp;</p></td><td><p>Rash</p></td><td><p>Alopecia, eczema, pruritus,</p></td><td><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Muscular weakness, myalgia</p></td><td><p>Rhabdomyolysis and blood creatine phosphokinase increased*</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>&nbsp;</p></td><td><p>Asthenia/fatigue</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Injury, poisoning and procedural complications</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Injury</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>* Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.</p><p><u>Description of selected adverse reactions</u><br />The risk of anorexia is higher when levetiracetam is co-administered with topiramate.<br />In several cases of alopecia, recovery was observed when levetiracetam was discontinued.<br />Bone marrow suppression was identified in some of the cases of pancytopenia.<br />Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.</p><p><u>Paediatric population</u><br />In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. Sixty of these patients were treated with levetiracetam in placebo-controlled studies. In patients aged 4 &ndash; 16 years, a total of 645 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these paediatric age ranges, these data are supplemented with the post-marketing experience of the use of levetiracetam.<br />In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy.<br />The adverse reaction profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical studies were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.<br />A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL &ndash; Achenbach Child Behavior Checklist). However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.</p><p><u>To reports any side effect(s):</u></p><ul><li><strong><em>Saudi Arabia:</em></strong></li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><ul><li>Fax: +966 11 205 7662</li><li>SFDA Call Center: 19999</li><li>Email: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><ul><li><strong><em>Other GCC States:</em></strong></li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u><br />Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses.</p><p><u>Management of overdose</u><br />After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60% for levetiracetam and 74% for the primary metabolite.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14<br />The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of &alpha;-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.</p><p><u>Mechanism of action</u><br />The mechanism of action of levetiracetam still remains to be fully elucidated. <em>In vitro </em>and <em>in vivo </em>experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.<br /><em>In vitro </em>studies show that levetiracetam affects intraneuronal Ca<sup>2+</sup> levels by partial inhibition of N-type Ca<sup>2+</sup> currents and by reducing the release of Ca<sup>2+</sup> from intraneuronal stores. In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and &beta;-carbolines. Furthermore, levetiracetam has been shown in <em>in vitro </em>studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.</p><p><u>Pharmacodynamic effects</u><br />Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.<br />In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.</p><p><u>Clinical efficacy and safety</u><br /><em>Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.</em><br />In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6% for patients on placebo.</p><p><u>Paediatric population</u><br />In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).<br />44.6% of the levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year.<br />In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days. In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study. The total daily dose was administered twice daily.<br />The primary measure of effectiveness was the responder rate (percent of patients with &ge; 50% reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG. The efficacy analysis consisted of 109 patients who had at least 24 hours of video EEG in both baseline and evaluation periods. 43.6% of the levetiracetam treated patients and 19.6% of the patients on placebo were considered as responders. The results are consistent across age group. With continued long-term treatment, 8.6% of the patients were seizure-free for at least 6 months and 7.8% were seizure-free for at least 1 year.<br />35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged &lt; 6 months.<em>&nbsp;</em></p><p><em>Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.</em><br />Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400 &ndash; 1200 mg/day or levetiracetam 1000 &ndash; 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.<br />Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95% CI: -7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6% and 58.5% of subjects on levetiracetam and on carbamazepine CR respectively).<br />In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).</p><p><em>Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</em><br />Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. The majority of patients presented with juvenile myoclonic epilepsy.<br />In this study, levetiracetam, dose was 3000 mg/day given in 2 divided doses.<br />58.3% of the levetiracetam treated patients and 23.3% of the patients on placebo had at least a 50% reduction in myoclonic seizure days per week. With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0% were free of myoclonic seizures for at least 1 year.</p><p><em>Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.</em><br />Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.<br />72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week. With continued long-term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.<br />Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. Therefore, there is no need for plasma level monitoring of levetiracetam.<br />A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).</p><p><u>Adults and adolescents<br />Absorption</u><br />Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100%.<br />Peak plasma concentrations (C<sub>max</sub>) are achieved at 1.3 hours after dosing. Steady-state is achieved after two days of a twice daily administration schedule.<br />Peak concentrations (C<sub>max</sub>) are typically 31 and 43 &mu;g/ml following a single 1000 mg dose and repeated 1000 mg twice daily dose, respectively.<br />The extent of absorption is dose-independent and is not altered by food.</p><p><u>Distribution</u><br />No tissue distribution data are available in humans.<br />Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (&lt; 10%).<br />The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.</p><p><u>Biotransformation</u><br />Levetiracetam is not extensively metabolised in humans. The major metabolic pathway (24% of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P<sub>450</sub> isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.<br />Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6% of the dose) and the other one by opening of the pyrrolidone ring (0.9% of the dose).<br />Other unidentified components accounted only for 0.6% of the dose.<br />No enantiomeric interconversion was evidenced <em>in vivo </em>for either levetiracetam or its primary metabolite.<br /><em>In vitro</em>, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P<sub>450</sub> isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the <em>in vitro </em>glucuronidation of valproic acid.<br />In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and <em>in vivo </em>interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected <em>in vivo</em>. Therefore, the interaction of Neuritam with other substances, or <em>vice versa, </em>is unlikely.</p><p><u>Elimination</u><br />The plasma half-life in adults was 7&plusmn;1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.<br />The major route of excretion was via urine, accounting for a mean 95% of the dose (approximately 93% of the dose was excreted within 48 hours). Excretion <em>via </em>faeces accounted for only 0.3% of the dose.<br />The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66% and 24% of the dose, respectively during the first 48 hours.<br />The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. Levetiracetam elimination is correlated to creatinine clearance.</p><p><u>Elderly</u><br />In the elderly, the half-life is increased by about 40% (10 to 11 hours). This is related to the decrease in renal function in this population (see section 4.2).</p><p><u>Renal impairment</u><br />The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of Neuritam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).<br />In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.<br />The fractional removal of levetiracetam was 51% during a typical 4-hour dialysis session.</p><p><u>Hepatic impairment</u><br />In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50% due to a concomitant renal impairment (see section 4.2).</p><p><u>Paediatric population</u><br /><em>Children (4 to 12 years)</em><br />Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30% higher than in epileptic adults.<br />Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.<em>&nbsp;</em></p><p><em>Infants and children (1 month to 4 years)</em><br />Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).<br />In the population pharmacokinetic analysis conducted in patients from 1 month to 16 years of age, body weight was significantly correlated to apparent clearance (clearance increased with an increase in body weight) and apparent volume of distribution. Age also had an influence on both parameters. This effect was pronounced for the younger infants, and subsided as age increased, to become negligible around 4 years of age.<br />In both population pharmacokinetic analyses, there was about a 20% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential.<br />Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.<br />No adverse reactions on male or female fertility or reproduction performance were observed in rats at doses up to 1800 mg/kg/day (&times; 6 the MRHD on a mg/m<sup>2</sup> or exposure basis) in parents and F1 generation.<br />Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day. At 3600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. There was no effect on embryo-mortality and no increased incidence of malformations. The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (&times; 12 the MRHD on a mg/m<sup>2</sup> basis) and 1200 mg/kg/day for fetuses.<br />Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day. The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of fetuses with cardiovascular/skeletal anomalies. The NOAEL was &lt; 200 mg/kg/day for the dams and 200 mg/kg/day for the fetuses (equal to the MRHD on a mg/m2 basis).<br />A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day. The NOAEL was &ge; 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (&times; 6 the MRHD on a mg/m<sup>2</sup> basis).<br />Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (&times; 6 &ndash; 17 the MRHD on a mg/m<sup>2</sup> basis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u><br />Crosscarmelose sodium<br />Polyethylene glycol<br />Colloidal anhydrous silica<br />Magnesium stearate</p><p><u>Film-coating</u><br />Polyethylene glycol<br />Polyvinyl alcohol<br />Talc<br />Titanium dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear<strong> </strong>PVC film with aluminum blister foil placed into cardboard boxes containing 30 tablets (10 tablets x 3 strips).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Pharmaceutical Industries
P.O. Box No.: 355127, Riyadh 11383
Kingdom of Saudi Arabia.
Tel: (+96611) 2650450, 2650354
Fax: (+96611) 2650383
Email: info@saudi-pharma.net
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>